We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,924.00
Bid: 1,923.00
Ask: 1,925.00
Change: -6.00 (-0.31%)
Spread: 2.00 (0.104%)
Open: 1,937.00
High: 1,947.00
Low: 1,916.00
Prev. Close: 1,930.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Broker tips: Johnston Press, Direct Line, Hikma Pharmaceuticals

Thu, 04th Aug 2016 11:01

(ShareCast News) - Johnston Press shares plunged on Thursday as Numis placed its rating and target price 'under review' after the company swung to a first half loss.For the 26 weeks to 2 July, the company posted a statutory pre-tax loss of £183.7m versus a £2.2m profit the year before, as it booked a £183.6m non-cash impairment reflecting a change of assumptions on its publishing titles and print assets.Advertising revenues were down 17.9% in the first quarter but improved marginally, with a 15% drop in the second quarter despite the impact of the run-up to and uncertainty following the UK's vote to leave the European Union in June.Chief executive Ashley Highfield said the market continues to be challenging and uncertainty surrounding the outcome of the Brexit negotiations has caused further softness in some segments of the advertising market, in June and July.Numis said the half year results came in below its estimates at every level."Our key issue at Johnston remains debt which has risen to £209m (from £179.4m) representing almost 4x our annualised EBITDA."This material debt pile, relative to cashflows, in combination with the declining and uncertain trading environment place a significant question mark on the equity value in the business."Numis said it expects to cut estimates "reasonably sharply" in both fiscal years 2016 and 2017. Direct Line Insurance Group's rating has been downgraded to 'hold' from 'buy' by Berenberg as the broker said "questions remain about earnings sustainability"."We believe there is some risk regarding the sustainability of Direct Line's earnings," Berenberg said in a note on Wednesday."High reserve releases, lower than forecast cost savings and a shrinking direct market all cast doubt on future earnings."Berenberg said older accident years have been incredibly profitable for Direct Line but these years are now contributing increasingly less releases.The broker said it does not expect to see the same developments in more recent accident years. Berenberg believes it will be difficult for management to offset falling reserve releases with the current accident year and operating improvements."As reserve releases decline, we expect earnings to be flat at best, thus we believe it will be challenging to grow the dividend from here," the broker said.Berenberg reiterated a target price of 406p.Direct Line on Tuesday posted its half year report for the six months to 30 June on Tuesday. Operating profit fell 5% to £316.9m, hurt by lower investment gains and the new Flood Re levy, but the group beat its own consensus estimates of £263m. Analysts at Citi downgraded their recommendation on shares of Hikma Pharmaceuticals in the wake of the company´s trading update which was issued after the close of trading in London on 3 August.Hikma flagged new drug approvals were arriving more slowly than expected and the phasing of litigation costs at US generics.On the basis of the above, the broker´s analysts lowered their recommendation on the shares from 'buy' to 'neutral' and set a target price of 2,600p.They also lowered estimates for the drugmaker´s core 2016 earnings before interest and taxes and earnings per share by 9.0% to $367m and $1.08, respectively - below the equivalent figures of $420m and $1.22 expected by the consensus.EPS estimates from 2017 onwards were cut by between 2% and 5% from 2017 onwards, with rates in foreign exchange markets expected to be an "incremental headwind".What was Citi´s view? "Developments at US Generics at best can be described as a 'short term hiccup'. At worse, sentiment concerns around the revenue/margin potential from the Roxane pipeline will increase, which is not helped by the lack of clarity on the pipeline given commercial sensitivities until 2017."If one were to cut his Roxane pipeline estimates by half, that would lead to EPS downgrades of between -15.0% and -20.0%, Citi said.Citi estimated the company´s net present value (NPV) at 2,900p, with a weighted average cost of capital of 8.0%, a terminal growth value (the rate at which free cash flows are expected to grow for eternity) of 2.0% and cable´s exchange rate at 1.32.
More News
5 Aug 2022 08:15

LONDON BRIEFING: London Stock Exchange benefits from market volatility

(Alliance News) - London Stock Exchange Group on Friday said results in the first half of 2022 improved, as this year's interim period had an extra month's worth of contribution from recent acquisition Refinitiv.

Read more
4 Aug 2022 17:05

LONDON MARKET CLOSE: Stocks shrug off BoE's UK recession warning

(Alliance News) - Stocks in London managed to end higher on Thursday despite a bleak warning from the Bank of England regarding to outlook for the UK economy as it jacked up rates by 50 basis points.

Read more
4 Aug 2022 12:09

LONDON MARKET MIDDAY: BoE hikes, expects UK recession in 4th quarter

(Alliance News) - London shares price made some gains on Thursday morning, though these fell well short of the market rise seen on mainland Europe, as traders in London showed signs of trepidation leading up to the Bank of England's interest rate decision.

Read more
4 Aug 2022 10:15

Hikma revenue flat, profits tumble in first half

(Sharecast News) - Hikma shares were tumbling on Thursday morning after the pharmaceuticals company reported flat group revenue in its first half, at $1.21bn, as it slashed its guidance on its lagging generics business.

Read more
4 Aug 2022 09:01

LONDON MARKET OPEN: FTSE 100 underperforms amid pre-BoE trepidation

(Alliance News) - The FTSE 100 underperformed European peers and traded sideways in early dealings on Thursday, with the Bank of England to take centre-stage during a week that so far has been dominated by tensions between the US and China.

Read more
4 Aug 2022 09:00

TOP NEWS: Hikma first half hit by stiff competition for Generics

(Alliance News) - Hikma Pharmaceuticals PLC shares suffered on Thursday, as it lowered annual guidance after a poor performance in its Generics business hit half-year profit.

Read more
4 Aug 2022 07:54

LONDON MARKET PRE-OPEN: Next and Serco up outlook but Hikma lowers

(Alliance News) - Stock prices in London are seen opening ever-so-slightly higher, falling short of the more convincing gains seen in Asia, with investors wary ahead of the latest Bank of England interest rate decision.

Read more
28 Jul 2022 16:06

UK earnings, trading statements calendar - next 7 days

Friday 29 July 
Allianz Technology Trust PLCHalf Year Results
Aston Martin Lagonda Global Holdings PLCHalf Year Results
AstraZeneca PLCHalf Year Results
Babcock International Group PLCFull Year Results
CMC Markets PLCTrading Statement
Croda International PLCHalf Year Results
Glencore PLCTrading Statement
Jupiter Fund Management PLCHalf Year Results
IMI PLCHalf Year Results
Impellam Group PLCHalf Year Results
Industrials REIT LtdTrading Statement
International Consolidated Airlines Group SAHalf Year Results
Intertek Group PLCHalf Year Results
Law Debenture Corp PLCHalf Year Results
Morgan Advanced Materials PLCHalf Year Results
NatWest Group PLCHalf Year Results
Premier Miton Global Renewables Trust PLCHalf Year Results
Rightmove PLCHalf Year Results
Shearwater Group PLCFull Year Results
Standard Chartered PLCHalf Year Results
Walker Crips Group PLCFull Year Results
YouGov PLCTrading Statement
Monday 1 August 
Ascential PLCHalf Year Results
Cranswick PLCQ1 Results
Dialight PLCHalf Year Results
GlobalData PLCHalf Year Results
HSBC Holdings PLCHalf Year Results
Hutchmed (China) LtdHalf Year Results
NAHL Group PLCTrading Statement
Pearson PLCHalf Year Results
Senior PLCHalf Year Results
Seraphine Group PLCFull Year Results
Spectris PLCHalf Year Results
XP Power PLCHalf Year Results
Tuesday 2 August 
BP PLCHalf Year Results
Capital & Counties Properties PLCHalf Year Results
Coats Group PLCHalf Year Results
Devro PLCHalf Year Results
Direct Line Insurance Group PLCHalf Year Results
Domino's Pizza Group PLCHalf Year Results
Fresnillo PLCHalf Year Results
Greggs PLCHalf Year Results
Keller Group PLCHalf Year Results
Man Group PLCHalf Year Results
Rotork PLCHalf Year Results
Sage Group PLCQ3 Results
Staffline Group PLCHalf Year Results
Synthomer PLCHalf Year Results
Travis Perkins PLCHalf Year Results
Virgin Money UK PLCQ3 Results
Wednesday 3 August 
Endeavour Mining PLCHalf Year Results
Ferrexpo PLCHalf Year Results
Hill & Smith Holdings PLCHalf Year Results
Hiscox LtdHalf Year Results
IP Group PLCHalf year Results
LSL Property Services PLCHalf Year Results
Taylor Wimpey PLCHalf Year Results
Thursday 4 August 
Coca-Cola Europacific Partners PLCHalf Year Results
ConvaTec Group PLCHalf Year Results
Evraz PLCHalf Year Results
Glencore PLCHalf Year Results
Gym Group PLCHalf Year Results
Hikma Pharmaceuticals PLCHalf Year Results
Meggitt PLCHalf Year Results
Mondi PLCHalf Year Results
Morgan Sindall Group PLCHalf Year Results
Next PLCTrading Statement
Pantheon International PLCFull Year Results
Revolution Beauty Group PLCFull Year Results
Rolls-Royce Holdings PLCHalf Year Results
ScS Group PLCTrading Statement
Secure Trust Bank PLCHalf Year Results
Serco Group PLCHalf Year Results
Spirent Communications PLCHalf Year Results
Tritax Big Box REIT PLCHalf Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
18 Jul 2022 09:46

LONDON BROKER RATINGS: Trio of downgrades for Fevertree; Admiral cut

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
13 Jul 2022 10:02

LONDON BROKER RATINGS: Jefferies likes Tyman; UBS cuts Beazley

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
25 May 2022 10:05

LONDON BROKER RATINGS: JPMorgan cuts Hikma; Liberum likes Trustpilot

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
25 May 2022 08:28

LONDON BRIEFING: M&S warns on cost hit to profit but is well placed

(Alliance News) - Marks & Spencer on Wednesday reported a swing to profit for the year ended April 2, but the clothing, homewares and food retailer cautioned on profit in the year ahead, amid the war in Ukraine and investment plans.

Read more
24 May 2022 10:29

IN BRIEF: Hikma Pharmaceuticals Chief Executive Siggi Olafsson resigns

Hikma Pharmaceuticals PLC - London-based pharmaceutical company - Says Siggi Olafsson has resigned as chief executive officer and from the board to "pursue other opportunities." Adds he will remain available to the company until he resigns on June 24. Olafsson was appointed as CEO in 2018. Before he joined Hikma, he was president of peer firm Actavis Generics until 2014 from 2012.

Read more
24 May 2022 08:24

LONDON BRIEFING: Barclays launches delayed GBP1 billion share buyback

(Alliance News) - Barclays said it will kick off a GBP1.00 billion share buyback programme on Tuesday. The programme, initially announced in February, had been delayed in March after the bank admitted it sold more financial products to investors than it was allowed to.

Read more
24 May 2022 07:09

Hikma's Siggi Olafsson stands down as CEO

(Sharecast News) - Drugmaker Hikma Pharmaceuticals revealed on Tuesday that chief executive Siggi Olafsson has resigned from both the role and the company's board of directors in order to pursue other opportunities.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.